Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 PR Newswire GERMANTOWN, Md., July 21, 2026 GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen...
PR Newswire
More News
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
Key PointsCFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a total value of approximately $1.11 million, based on a weighted average price of $5.57 per share...
Nasdaq News: Markets
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Key Points41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026...
Nasdaq News: Markets
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices...
PR Newswire
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete...
PR Newswire
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States PR Newswire GERMANTOWN, Md., May 27, 2026 FDA grants orphan drug exclusivity for...
PR Newswire
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire GERMANTOWN, Md., May 26, 2026...
PR Newswire
Precigen’s Lead Cancer Therapy Is Fueling A Massive Stock Rally — Here’s What Wall Street Sees Next
Driven by Papzimeos sales, Precigen posted a revenue of $23.3 million, which came in above Wall Street’s estimates of $20.8 million, according to Fiscal.ai data.
Stocktwits
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen (PGEN) delivered earnings and revenue surprises of +20.00% and +9.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
>

Advertisement|Remove ads.